Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Talabostat and Cisplatin in Advanced Melanoma
This study has been completed.
Study NCT00083252   Information provided by Point Therapeutics
First Received: May 14, 2004   Last Updated: June 7, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma
Skin Cancer
Additional conditions recognized in this trial
Skin Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Skin Diseases
Interventions listed in this trial
talabostat (PT-100) tablets
cisplatin
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Point Therapeutics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services